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Background: It is currently unclear whether the additive effects of a long-acting b2-agonist
(LABA) and the antimuscarinic tiotropium bromide (TIO) on resting lung function are translated
into lower operating lung volumes and improved exercise tolerance in patients with chronic
obstructive pulmonary disease (COPD).
Methods: On a double-blind and cross-over study, 33 patients (FEV1Z 47.4  12.9% predicted)
were randomly allocated to 2-wk formoterol fumarate 12 mg twice-daily (FOR) plus TIO 18 mg
once-daily or FOR plus placebo (PLA). Inspiratory capacity (IC) was obtained on constant-speed
treadmill tests to the limit of tolerance (Tlim).
Results: FOR-TIO was superior to FOR-PLA in increasing post-treatment FEV1 and Tlim
(1.34  0.42 L vs. 1.25  0.39 L and 124  27% vs. 68  14%, respectively; p < 0.05). FOR-
TIO slowed the rate of decrement in exercise IC compared to FOR-PLA (Disotime-rest Z
0.27  0.40 L vs. 0.45  0.36 L, p < 0.05). In addition, end-expiratory lung volume (% total
lung capacity) was further reduced with FOR-TIO (p < 0.05). Of note, patients showing greater
increases in Tlim with FOR-TIO (16/26, 61.6%) had more severe airways obstruction and lower
exercise capacity at baseline. Improvement in Tlim with FOR-TIO was also related to larger
increases in FEV1 (p < 0.05).1 5571 8384; fax: þ55 11 5575 2843.
.com (D.C. Berton), albneder@pneumo.epm.br (J.A. Neder).
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Formoterol and tiotropium in COPD 1289Conclusions: Compared to FOR monotherapy, FOR-TIO further improved effort-induced
dynamic hyperinflation and exercise endurance in patients with moderate-to-severe COPD.
These beneficial consequences were more likely to be found in severely-disabled patients with
larger resting functional responses to the combination therapy.
Trial registration: Clinicaltrials.gov Identifier: NCT00680056 [ClinicalTrials.gov].
ª 2010 Elsevier Ltd. All rights reserved.Figure 1 Study design. Definition of abbreviations:
PFTs Z pulmonary function tests; incCPX Z symptom-limited
incremental cardiopulmonary exercise test; ctCPXZ constant-
speed cardiopulmonary exercise test; BDIZ Baseline Dyspnoea
Index; TDI Z Transitional Dyspnoea Index.Introduction
Inhaled bronchodilators remain the mainstay of the treat-
ment of exercise intolerance in patients with chronic
obstructive pulmonary disease (COPD).1 Current guidelines
recommend that regular use of long-acting bronchodilators is
safer and more effective than treatment with short-acting
drugs in chronically-dyspnoeic patients.2 Combining bron-
chodilators of different pharmacological classesmay improve
efficacy and diminish the risk of side-effects compared to
increasing the dose of a single agent.2 From the commer-
cially-available long-acting b2-adrenoceptor agonists
(LABAs), formoterol fumarate (FOR) is particularly attractive
as it combines rapid-onset with long-acting effects.3 Since
FOR and the long-acting antimuscarinic (LAMA) tiotropium
bromide (TIO) have potent deflationary effects on the lung-
chest wall system4e6 and FOR adds full b2-agonism
3 with
a greater peak effect than TIO,7 these drugs appear highly
complementary.8 In fact, there is mounting evidence that
FOR-TIO combination adds benefit to these drugs on isolation
to improve lung function, dyspnoea, health-relatedquality of
life, and incidence of adverse events.9e15
In this context, it is well-established that dynamic
hyperinflation (DH) is the key pathophysiological abnor-
mality associated with effort-induced breathlessness and
exercise intolerance in patients with COPD.16 Not surpris-
ingly, improvements in DH, dyspnoea, and tolerance to
a constant work rate cardiopulmonary exercise test (ctCPX)
have been progressively recognized as important outcomes
in pharmacological trials involving these patients.17 In fact,
positive changes on these markers of cardio-respiratory
impairment showed to be more closely related to
decreased daily-life dyspnoea and enhanced quality of life
than traditional indexes of airflow obstruction at rest.18,19
Surprisingly, however, no published study has to date
evaluated whether FOR-TIO is actually superior to FOR
monotherapy in improving effort-related DH and, conse-
quently, ctCPX performance in patients with COPD.
Our aim, therefore,was to investigatewhether once-daily
TIO would add to twice-daily FOR in order to further reduce
DH and improve exercise endurance compared to FOR plus
placeboTIO (PLA) inpatientswithmoderate-to-severeCOPD.
Secondarily, we evaluated whether the combination would
also decrease exercise-related and daily-life breathlessness.
Methods
Subjects
Thirty three ex-smokers (26 males) with stable COPD
(forced expiratory volume in 1 s [FEV1]/forced vital
capacity [FVC] < 0.7 and post-bronchodilator FEV1 < 70%predicted) presenting with a long history of smoking (>20
pack-years) and chronic breathlessness (Baseline Dysponea
Index (BDI) total score <9)20 were enrolled. Main exclusion
criteria were: recent exacerbation (within 1 month), long-
term oxygen therapy or arterial oxygen saturation <85% at
rest, and treatment with oral corticosteroids and anti-his-
taminics. All subjects gave written, informed consent (as
approved by the Institutional Medical Ethics Committee).
Study design
This was a randomized, double-blind, placebo-controlled,
and cross-over trial. Patients were assigned to a 2-week
treatment period with formoterol fumarate (FOR) dry
powder capsules 12 mg bid (Fluir, Mantecorp Plc, Rio de
Janeiro, Brazil) and placebo (PLA) o.d. via Handihaler
(Boehringer Ingelheim GmbH, Ingelheim, Germany) or FOR
and tiotropium bromide (TIO) dry powder capsules 18 mg o.
d. via Handihaler (Spiriva, Boehringer Ingelheim GmbH,
Ingelheim, Germany) (Fig. 1). After a screening visit (day e
7), patients discontinued all long-acting bronchodilators.
During the study, patients were given a Combivent
metered-dose inhaler (salbutamol 120 mg/ipratropium 20 mg
per actuation, Boehringer Ingelheim) and instructed to use
2 puffs each 4 h as rescue medication. Use of inhaled or
nasal corticosteroids and oral modified-release theophyl-
line or derivatives was allowed provided dose, schedule and
formulation remained unchanged.
Protocol
At visit 1, patients underwent clinical evaluation, pulmo-
nary function testing (including blood gas analysis), and
1290 D.C. Berton et al.a symptom-limited incremental cardiopulmonary exercise
test on a motorized treadmill (incCPX). On visits 2e5,
subjects performed CPX tests at 2% grade (ctCPX) to the
limit of tolerance (Tlim) at 75e80% of the maximal speed
reached on the incCPX. Activity-related breathlessness
(BDI) was assessed at the beginning and changes in daily
breathlessness (Transitional Dyspnoea Index; TDI)20 were
recorded at the end of each treatment period (Fig. 1).
Measurements
Activity-related breathlessness
A single investigator, who was blinded to the treatment
received by the patient, applied the BDI and TDI ques-
tionnaires.20 This instrument has been validated by
assessing short-term (2 weeks) changes in dyspnoea in
patients with COPD.13
Pulmonary function tests
Spirometric tests were performed by using a calibrated
pneumotachograph (CPF System, Medical Graphics
Corporation e MGC, St Paul, MN, USA). FVC (L), FEV1 (L) and
inspiratory capacity (IC, L) were measured at visit 1 (before
and 20 min after inhalation of salbutamol 400 mg via
metered-dose inhaler), at visits 2 and 4 (before the exer-
cise tests) and at visits 3 and 5 (before and 2 h after the
study medications). Residual volume (RV, L) and total lung
capacity (TLC, L) were measured on a constant-volume
body plethysmograph (Elite System, MGC).21 The single
breath transfer factor for carbon monoxide (DLCO,
mL min1 mmHg1) was measured using the 1085D System
(MGC).22 Arterial partial pressures for O2 and CO2 (ABL 330;
Radiometer, Copenhagen, Denmark) were determined in
standard anaerobic conditions (PaO2 and PaCO2, mmHg)
from samples taken by radial artery puncture in patients.
Exercise tests
Cardiopulmonary exercise tests (CPX) were performed on
a treadmill (Super ATL, Inbrasport, RS, Brazil) with the
patients being instructed to avoid handling the sidebars
unless necessary for stabilization purposes. Oxygen uptake
( _VO2, mL/min); ventilation ( _VE, L/min); tidal volume (VT,
L); and total expiratory time (s) were recorded and
expressed as 15-s means (CardiO2 System, MGC). Heart
rate (HR, beats/min) was determined from the ReR interval
of a 12-lead electrocardiogram and arterial oxyhemoglobin
saturation (SpO2) by pulse oximetry. Subjects rated their
shortness of breath and leg effort using the 0e10 Borg
scale.23 During the incremental CPX (incCPX), speed was
increased each minute from a baseline of 2 min of gentle
walking (1.2 km/h and 2% grade) at a constant rate
(0.5e0.8 km/h) to the limit of tolerance.24 The constant-
speed exercise tests (ctCPX) were performed to the point
when the subject could no longer maintain the required
walking speed despite active encouragement (Tlim, s) or
a time-limited of 20 min had been reached. After 2 min of
gentle walking (1.2 km/h), the subjects exercised at
75e80% of the maximal speed obtained in the incCPX at 2%
grade. Assuming that resting TLC remains constant during
exercise, changes in IC were taken to reflect changes in
end-expiratory lung volume (i.e. EELVZ TLC  IC).4e6,16,17
The patients rated shortness of breath, leg effort andperformed IC maneuvers each 2 min. Exercise responses
were compared at an individual isotime. i.e., the longest
time duration common to all ctCPXs in a given subject.
Data analysis
The primary efficacy variable was Tlim % of change from
baseline (post-pre/pre) in the ctCPXs. The required sample
size (NZ 24) was calculated using a two-sided t-test taking
into consideration a 2  2 cross-over design in order to ach-
ieve a between-treatment difference in DTlim of 20% with
b and a errors set at 15% and 5%, respectively. Patients who
walked more than 20 min at one of the baseline visits were
excluded from the analyses as such tests were judged inap-
propriately long to evaluate the intervention effects.25,26
Otherwise stated, data are reported as mean  SD or
median (range). Repeated measures analysis of variance
(ANOVA) was used to test for significant differences at
different visits and time points according to each treat-
ment. Non-paired or paired t-tests were used as appro-
priate. Pearson’s product moment correlation was used to
assess the level of association between continuous vari-
ables. Differences were declared significant if p < 0.05.
Results
Population characteristics
On average, randomized patients had moderate-to-severe
airflow obstruction with increased static lung volumes and
reductions in DLCO (Table 1). Patients typically presented
with poorly reversible airflow obstruction and only 2
patients met the criteria for significant bronchodilator
reversibility (DFEV1 > 12% and 200 mL from pre-dose
values).27 As expected, they had reduced peak aerobic
capacity and breathlessness as the main exercise limiting
symptom (Table 1).
Bronchodilator effects on spirometric variables and
daily-life dyspnoea
Four patients were excluded from the study due to COPD-
relatedexacerbations: 2during the run-inperiodand1patient
on each treatment (Fig. 2). After 2 weeks, both treatments
were associated with significant improvements in the main
spirometric variables comparing with trough and baseline
values (p< 0.05). However, FOR-TIO led to greater changes in
FEV1 than FOR-PLA; conversely, resting IC and other spiro-
metric variables improved similarly with both treatments
(Table 2). In addition, TDI scores increased to a larger extent
with FOR-TIO than FOR-PLA (Dchange Z 3.8  1.8 vs.
2.9  2.5, respectively; pZ 0.054).
Effects on exercise-related physiological and
subjective responses
Three additional patients were excluded from the exercise
analysis (Fig. 2) as they walked more than 20 min at one of
the baseline visits (see Methods). The main study outcome
(% improvement in Tlim from baseline) was significantly
greater after FOR-TIO than FOR-PLA treatment (124  27%
vs. 68  14%, p < 0.05; Fig. 3) (see also below).
Table 1 Baseline characteristics (N Z 33).
Variables Values
Anthropometric
Age, yrs 64.9  8.5
Male/female 26/7
Body Mass Index, kg m2 25.3  3.5
Pulmonary function
FEV1, L (% pred) 1.26  0.43 (47.4  12.9)
FVC, L (% pred) 2.86  0.88 (82.5  17.6)
FEV1/FVC 0.45  0.11
IC, L (% pred) 2.07  0.54 (80.2  18.2)
TLC, L (% pred) 6.12  0.99 (110.1  15.7)
RV, L (% pred) 3.17  0.73 (178.4  58.3)
DLCO, % pred 55.3  17.9
PaO2, mmHg 69.5  7.8
SaO2, % 93  2
PaCO2, mmHg 39.4  4.0
Peak exercise
_VO2, ml/min 1055  294
_VE, L 34.5  12.4
_VE/MVV 0.73  0.16
SpO2, % 86  6
HR, % pred 85.4  11.3
_VO2/HR, ml/min/beat 7.9  2.0
Borg dyspnoea scores 7 (3e10)
Borg leg effort scores 6 (0e10)
Values are means  standard deviation with exception of symptoms (median and range).
Definition of abbreviations: FEV1Z forced expiratory volume in 1 s; FVCZ forced vital capacity; ICZ inspiratory capacity; TLCZ total
lung capacity; RV Z residual volume; DLCO Z lung diffusing capacity for carbon monoxide; Pa Z arterial pressure; Sa Z arterial
saturation; _VO2Zoxygen uptake; _VCO2Zcarbon dioxide output; _VEZminute ventilation; MVV Z maximal voluntary ventilation;
SpO2 Z oxyhemoglobin saturation by pulse oximetry; HR Z heart rate.
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increases in ventilatory reserve (as suggested by lower VE/
MVV ratio) at “isotime”. Although either FOR-TIO or FOR-
PLA significantly increased VT and IC, these changes tended
to be larger with the combination therapy (“mean”
DchangeZ 0.16 L vs. 0.08 L, pZ 0.17; and 0.33 L vs 0.19 L,
p Z 0.089; respectively). In fact, FOR-TIO was associated
with lower decrements of IC from rest and, consequently,
decreased EELV (% TLC) than FOR-PLA at isotime (Table 3
and Fig. 4, respectively; p < 0.05); in addition, mean
expiratory flow (VT/TE) was larger with the former treat-
ment (Table 3; p < 0.05). Conversely, there were no
between-treatment differences in the magnitude of
improvement in Borg dyspnoea scores (Table 3).
Heterogeneity on exercise responses
From the inspection of Fig. 3, it was evident a larger
heterogeneity in DTlim response with FOR-TIO than FOR-
PLA. Therefore, DTlim was higher with FOR-TIO than FOR-
PLA in 16/26 (61.6%) exercise “improvers” with the
combination (548  92 s vs 236  58 s, respectively;
p < 0.01); conversely, DTlim was lower with FOR-TIO in the
remaining 10/26 (38.4%) “non-improvers” (194  50 s vs.
377s  68 s, respectively; p < 0.05). Interestingly, exercise
“improvers” with FOR-TIO had lower Tlim at baseline andthere was a significant association between severe airflow
obstruction (<1.2 L, w40% predicted) and improvement in
TLim with FOR-TIO (p < 0.05) (Table 4). Moreover,
“improvers” had greater increases at the end of FOR-TIO
treatment in FEV1 (pZ 0.04) and, marginally, IC (pZ 0.09)
(Fig. 5).
Discussion
This seems to constitute the first randomized and
controlled trial to investigate whether adding a LAMA
(TIO) to a LABA (FOR) is superior to FOR monotherapy in
improving effort-related DH and exercise endurance in
patients with moderate-to-severe COPD. As previously
shown,9,11e13 FOR-TIO increased FEV1 compared to FOR
plus placebo (PLA). Whilst the combination therapy did
not additionally improve resting IC, FOR-TIO was associ-
ated with larger mean expiratory flows and slower
kinetics of exercise-induced DH than FOR-PLA. These
effects might have been instrumental to explain the
greater improvement in exercise tolerance and daily-life
dyspnoea found with the combination therapy. Interest-
ingly, FOR-TIO was particularly advantageous to patients
with poorer exercise capacity in whom the combination
was more effective than FOR-PLA in enhancing airflow
obstruction. These data, therefore, not only provide
Figure 2 The CONSORT diagram of the study.
1292 D.C. Berton et al.novel evidence that the positive effects of FOR-TIO on
resting lung function are translated into clinically-mean-
ingful changes in key exercise-related outcomes but also
give a mechanistic explanation for these beneficial find-
ings in patients with COPD.Table 2 Treatment differences in lung function parameters at
post-dose) (N Z 29).
Variable Formoterol þ Placebo
Baseline Pre Post
FEV1, L 1.13  0.41 1.14  0.38 1.25  0.3
FEV1, % pred 42  12 43  12 47  12*
FVC, L 2.61  0.96 2.58  0.95 2.86  1.0
FVC, % pred 73  17 72  16 80  20*
FEV1/FVC, % 44  11 45  11 45  11
IC, L 1.84  0.76 1.94  0.67 2.20  0.7
IC, % pred 69  24 75  20* 83  20*
Values are means  SD.
Definition of abbreviations: FEV1 Z forced expiratory volume in 1 s; F
from basal within a given treatment; yp < 0.05 post vs pre within a gMechanisms for a greater exercise improvement
with FOR-TIO than FOR-PLA
Bronchodilators play a pivotal role in the treatment of
symptomatic patients with COPD and the combined use ofbaseline and after a 2-week treatment period (pre- and 2 h
Formoterol þ Tiotropium
Baseline Pre Post
9*,y 1.13  0.41 1.19  0.42* 1.34  0.42*,y,z
,y 42  13 45  14* 51  14*,y,z
5*,y 2.58  0.97 2.69  0.98 2.95  0.99*,y
,y 72  18 75  17 83  19*,y
44  10 46  11 47  10
2*,y 1.83  0.79 1.97  0.63 2.20  0.68*,y
,y 71  26 77  24 85  22*,y
VC Z forced vital capacity; IC Z inspiratory capacity; *p < 0.05
iven treatment; zp < 0.05 between-treatment comparison.
Figure 3 Individual (dashed lines) and mean (solid lines)
values of percent changes in time to the limit of tolerance
(Tlim) after 2-wk treatment with formoterol plus placebo
(FOR-PLA) and formoterol plus tiotropium (FOR-TIO). *p < 0.01
from baseline; ybetween-treatments comparison.
Table 3 Isotime measurements during submaximal exercise in
(N Z 26).




1 1001  332 1005
_VCO2, ml min
1 944  310 912
RER 0.95  0.08 0.90
Ventilatory
_VE, L 31.7  11.2 32.0
_VE/MVV 0.79  0.20 0.71
VT 1.06  0.32 1.14
f, rpm 30  6 28
IC, L 1.40  0.42 1.59
ΔIC from rest, L 0.43  0.32 0.45
TI, s 0.72  0.13 0.80
VT/TE, L s
1 0.82  0.32 0.83
Cardiovascular
HR, bpm 126  17 122
_VO2/HR, ml min
1 bpm1 8.0  2.7 8.3
SBP, mmHg 178  17 175
HR  SBP 22 703  4502 21 72
Pulmonary gas exchange
SpO2, % 84  6 87
Subjective
Borg dyspnoea scores 7  (1e10) 5
Borg leg effort scores 3  (0e10) 3
Values are means  SD with exception of symptoms (median and ran
Definition of abbreviation: _VO2Zoxygen uptake; _VCO2Zcarbo
_VEZminute ventilation; MVV Z maximal voluntary ventilation; VT Z
TIZ inspiratory time; TEZ expiratory time; HRZ heart rate; SBPZ s
oximetry; *p < 0.05 from baseline; yp < 0.05 between-treatment com
Figure 4 End-expiratory lung volume (EELV) in percent of
total lung capacity (TLC) at rest and isotime (i.e., the shortest
test duration in a given subject) during submaximal exercise
tests after formoterol plus placebo (FOR-PLA :) and for-
moterol plus tiotropium (FOR-TIO B).
Formoterol and tiotropium in COPD 1293agents with different pharmacological mechanisms of
action is supported by current evidence-based guidelines.2
In fact, several clinical trials convincingly demonstrated
that adding TIO to FOR and vice-versa produces additivethe baseline visit and post-dose after a 2-week treatment
Formoterol þ Tiotropium
ent Baseline Treatment
 282 981  289 995  290
 279 921  301 934  296
 0.06 0.93  0.08 0.93  0.06
 10.4 31.7  11.9 33.4  11.7
 0.13* 0.80  0.20 0.68  0.13*
 0.3* 1.02  0.31 1.18  0.35*
 6* 31  8 28  7*
 0.41* 1.39  0.40 1.72  0.43*
 0.36 0.41  0.37 0.27  0.40y
 0.19* 0.71  0.14 0.84  0.17*
 0.29 0.82  0.36 0.90  0.34*
 17* 128  20 123  19*
 2.4 7.7  2.1 8.1  2.3
 19 178  17 169  22*
7  4314 23 030  4738 21 194  5086*
 6* 86  6 88  6*
 (0.5e9)* 7  (3e10) 5  (0e9)*
 (0e10) 4  (0e10) 2.5  (0e9)
ge).
n dioxide output; RER Z respiratory exchange rate;
tidal volume; f Z respiratory rate; IC Z inspiratory capacity;
ystolic blood pressure; SpO2Z oxyhemoglobin saturation by pulse
parison.
Table 4 Baseline characteristics contrasting patients with larger increases in Tlim with FOR-TIO than FOR-PLA (“improvers”)
and “non-improvers”.
Variables Improvers (N Z 16) Non-improvers (N Z 10)
Anthropometric
Age, yrs 64.1  7.7 65.0  6.9
Body mass index, kg/m2 25.3  3.6 25.0  3.2
Pulmonary function
FEV1, L (% pred) 1.19  0.41 (44.2  12.5) 1.33  0.43 (50.2  13.6)
FEV1 < 1.2 L, n (%) 13/16 (81)* 3/10 (30)
FVC, L (% pred) 2.72  0.92 (77.5  20.7) 3.11  1.02 (89.6  12.7)
IC, L (% pred) 1.92  0.47 (74.3  21.3) 2.33  0.65 (88.6  14.3)
TLC, L (% pred) 5.95  1.02 (104.2  15.3) 6.17  1.12 (115.1  12.4)
RV, L (% pred) 3.27  0.78 (180.0  45.6) 2.88  0.55 (167.8  57.3)
RV/TLC 0.50  0.17 0.47  0.09
DLCO, % pred 56.8  19.6 50.4  18.2
PaO2, mmHg 68.9  6.9 71.5  10.1
SaO2, % 93  2 94  2
PaCO2, mmHg 40.3  3.9 37.8  3.8
Peak exercise
_VO2, ml/min 1018  278 1092  274
_VE/MVV 0.73  0.13 0.77  0.19
SpO2, % 87  6 85  5
HR, % pred 81.4  9.3 88.5  12.1
_VO2/HR, ml/min/beat 7.9  2.0 7.9  2.0
Borg dyspnoea scores 7.0 (3e10) 7.5 (5e10)
Borg leg effort scores 4.0 (0e9) 7.0 (0e10)
Submaximal exercise
Tlim at baseline 418  193* 610  244
Values are means  standard deviation with exception of symptoms (median and range) and FEV1 < 1.2 L (number and proportion of
patients).
Definition of abbreviations: Tlim Z time at which patients could no longer maintain the required walking speed despite active
encouragement in the constant-speed exercise tests; FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity;
IC Z inspiratory capacity; TLC Z total lung capacity; RV Z residual volume; DLCO Z lung diffusing capacity for carbon monoxide;
PaZ arterial pressure; SaZ arterial saturation; _VO2Zoxygen uptake; _VEZminute ventilation; MVVZ maximal voluntary ventilation;
SpO2 Z oxyhemoglobin saturation by pulse oximetry; HR Z heart rate. *P < 0.05.
1294 D.C. Berton et al.benefits on resting pulmonary function.9e15 As previously
stressed, however, changes in airflow obstruction correlate
variably with effort-induced DH and exercise endurance16
which does relate well with patient’s quality of life18,19
and daily-life dyspnoea.28 The present study, therefore,
add novel information to the field as it is the first demon-
stration of the superior performance of FOR-TIO compared
to FOR-PLA on exercise-derived outcomes for the majority
of patients with moderate-to-severe COPD.
The main physiological explanation for the superiority
of FOR-TIO over FOR-PLA in improving exercise endurance
seems to rely on the ability of the combination therapy in
reducing the operating lung volumes during exercise.16
This is particularly important as resting lung hyperinfla-
tion did not differ between the treatments (Table 2).
Consequently, FOR-TIO treatment added to FOR-PLA in
slowing the rate of development of DH as indicated for
the lower decrement in IC from rest (Table 3). In this
context, the larger increases in mean expiratory flow (VT/
TE) with FOR-TIO than FOR-PLA might have been crucial
to allow a greater rate of lung emptying as exercise
progressed thereby minimizing air trapping at end-
expiration.29Surprisingly, however, breathlessness scores at isotime
were not further reduced with FOR-TIO (Table 3) as it would
be expected from the lower operating lung volumes and,
probably, improved neuromechanical coupling with the
combination therapy.30 It should be acknowledged that
discrete ratings of effort-related dyspnoea have not been
consistently responsive to interventions, especially when
the added physiological benefit is not particularly
large.31e33 In this context, it seems that a higher density of
measurement points (i.e., continuous ratings of dyspnoea)
are more sensitive31e33 and they should be considered in
future comparative trials involving ctCPX tests in patients
with COPD.
Heterogeneity on the exercise responses to
FOR-TIO
Another noticeable finding of the present study was the
lack of superiority of FOR-TIO over FOR-PLA in enhancing
exercise tolerance in more than a third of the patients
which was (over)compensated by the pronounced
improvement in Tlim in the sub-group of FOR-TIO
“improvers” (Fig. 5A). In this context, it might be
Figure 5 Comparative effects of 2-wk formoterol plus
placebo treatment (FOR-PLA) vs. FOR plus tiotropium (FOR-
TIO) on time to exercise intolerance (Tlim, panel A), airways
obstruction (FEV1, panel B) and inspiratory capacity (IC, panel
C ) in patients with larger increases in Tlim with FOR-TIO than
FOR-PLA (solid lines) and vice-versa (dashed lines). Data are
mean and SE. *p < 0.01 between-treatment for a given sub-
group.
Formoterol and tiotropium in COPD 1295speculated that any cholinergic blockade may have been
more critical in enhancing exercise tolerance in more
disabled patients. In fact, FOR-TIO “improvers” had worse
airflow obstruction and disease severity is moderately
related to cholinergic bronchomotor tone in patients with
COPD.34 It should also be acknowledged that there is
growing experimental evidence that cholinergic blockade is
not universally beneficial in the presence of b2-agonism.
35
Whilst this post-hoc finding should be viewed with caution
due to the small sample size and short period of interven-
tion of the present study, the response heterogeneity toFOR-TIO combination warrants further consideration in
larger trials.
Methodological considerations
This seems to constitute the first “head-to-head” compar-
ative study to contrast bronchodilator regimens which used
high-intensity walking instead of cycling as the exercise
modality. Apart from being a more natural mode of physical
exercise, walking has been more sensitivity to detect
positive effects of bronchodilators than cycling in patients
with COPD.36 Therefore, it is not only likely that our results
are externally valid but also this technical feature may help
explain the greater improvement in Tlim found in the
present study than typically reported in the literature.26
There is also a large body of evidence showing that high-
intensity, constant work rate exercise is the most sensitive
test format to unravel the beneficial effects of interven-
tions in patients with COPD (as reviewed in Ref. 17). Inter-
estingly, the hyperbolic nature of the power-Tlim
relationship in these patients37 may also help explaining the
large inter-subject variability on Tlim, i.e., the closer
the testing work rate to the asymptote (“critical power”),
the larger the potential for improvement. Finally, although
monotherapy with FOR and TIO had been considered to be
broadly equivalent,9,13 it remains to be formally evaluated
whether these results are also valid for FOR-TIO combina-
tion versus TIO monotherapy.10,38
Conclusions
The present study provided novel evidence that the
combination of a LABA (twice-daily FOR) to a LAMA (once-
daily TIO) is superior to FOR plus placebo in reducing the
rate of development of effort-induced DH with beneficial
consequences on exercise endurance capacity in patients
with moderate-to-severe COPD. These advantageous
effects of the FOR-TIO combination were more likely to be
found in patients who were severely-disabled and func-
tionally responsive to the addition of cholinergic blockade
to b2-adrenoceptor agonism.
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